Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_1
1
9%
Ph phase_2
10
91%

Phase Distribution

1

Early Stage

10

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
10(90.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(5)
Terminated(2)
Other(3)

Detailed Status

Completed5
unknown3
Not yet recruiting1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (9.1%)
Phase 210 (90.9%)

Trials by Status

unknown327%
completed545%
not_yet_recruiting19%
terminated19%
withdrawn19%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_1

Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer

NCT02386397
completedphase_2

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

NCT03092895
not_yet_recruitingphase_2

Golidocitinib Combined With GemOx in RR PTCL

NCT07279584
terminatedphase_2

Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma

NCT06941688
unknownphase_2

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

NCT05251662
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02386397Phase 1

Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer

Completed
NCT03092895Phase 2

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Completed
NCT07279584Phase 2

Golidocitinib Combined With GemOx in RR PTCL

Not Yet Recruiting
NCT06941688Phase 2

Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma

Terminated
NCT05251662Phase 2

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Unknown
NCT02624492Phase 2

To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

Completed
NCT02534337Phase 2

Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Withdrawn
NCT02836847Phase 2

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Unknown
NCT01888978Phase 2

Molecularly Tailored Therapy for Pancreas Cancer

Completed
NCT01487915Phase 2

Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma

Unknown
NCT01487720Phase 2

GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11